Bejrananda Tanan, Pripatnanont Choosak, Tanthanuch Monthira, Karnjanawanichkul Watid
J Med Assoc Thai. 2016 Dec;99(12):1315-21.
To retrospectively review the oncological outcome of docetaxel-based chemotherapy in men with metastatic castration-resistant prostate cancer (mCRPC).
The present study included 68 patients with mCRPC who were treated with 3-weekly docetaxel (75 mg/m2) plus prednisone between 2010 and 2014. The prognostic significance of several clinicopathologic factors in these patients were analyzed. The endpoints of oncological outcome were overall survival (OS). The effect of clinical variables on OS was statistically analyzed by a log-rank test or Cox regression with hazard ratios. All analyses were performed using a 0.05 level of significance.
In these 68 patients, the median age and serum value of prostate-specific antigen (PSA) prior to docetaxel-based chemotherapy were 69 years and 173 ng/ml, respectively. Of these patients, PSA decline ≥50% was observed in 46 patients (67.6%). The OS and progression-free survival were 25.4 and 11.7 months, respectively. Of several factors examined, univariate analysis identified PSA at diagnosis mCRPC, PSA at diagnosis of mCRPC, PSA at first cycle of CMT ≥150 ng/mL, number of CMT response ≤2 cycle as significant predictors of OS, of which only PSA at first cycle of CMT ≥150 ng/mL appeared to be independently related to poor OS on multivariate analysis.
Oncologic outcomes in mCRPC patients receiving docetaxel-based chemotherapy is generally favorable and only PSA at first cycle of CMT more than 150 ng/mL appeared to be independently related to poor OS on multivariate analysis.
回顾性分析多西他赛为主的化疗方案用于转移性去势抵抗性前列腺癌（mCRPC）男性患者的肿瘤学结局。
本研究纳入了68例mCRPC患者，这些患者在2010年至2014年间接受了每3周一次的多西他赛（75mg/m²）联合泼尼松治疗。分析了这些患者中几个临床病理因素的预后意义。肿瘤学结局的终点指标为总生存期（OS）。采用对数秩检验或Cox回归分析临床变量对OS的影响，并计算风险比。所有分析均采用0.05的显著性水平。
在这68例患者中，基于多西他赛化疗前的中位年龄和前列腺特异性抗原（PSA）血清值分别为69岁和173ng/ml。其中，46例患者（67.6%）观察到PSA下降≥50%。OS和无进展生存期分别为25.4个月和11.7个月。在检查的几个因素中，单因素分析确定mCRPC诊断时的PSA、CMT第一个周期时的PSA≥150ng/mL、CMT反应≤2个周期的次数为OS的显著预测因素，其中在多因素分析中只有CMT第一个周期时的PSA≥150ng/mL似乎与OS较差独立相关。
接受多西他赛为主化疗的mCRPC患者的肿瘤学结局总体良好，在多因素分析中只有CMT第一个周期时的PSA超过150ng/mL似乎与OS较差独立相关。
